AMNEAL PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of $57.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2026-06-30 was $57.65M, a 158.12% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2026-03-31 was $62.23M, a 414.02% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2025-12-31 was $35.04M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2025-09-30 was $2.29M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2025 was $71.77M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2024 was -$117.36M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2023 was -$79.27M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2022 was -$270.58M.
| Period end | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 8 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $57.65M 10-Q · filed 2026-08-06 | $119.88M 10-Q · filed 2026-08-06 | $154.92M derived: sum of 3 quarters · filed 2026-08-06 | $157.21M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $62.23M 10-Q · filed 2026-05-07 | $97.27M derived: sum of 2 quarters · filed 2026-05-07 | $99.56M derived: sum of 3 quarters · filed 2026-05-07 | $121.89M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $35.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $37.33M derived: sum of 2 quarters · filed 2026-02-27 | $59.66M derived: sum of 3 quarters · filed 2026-08-06 | $71.77M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $2.29M 10-Q · filed 2025-11-06 | $24.62M derived: sum of 2 quarters · filed 2026-08-06 | $36.73M 10-Q · filed 2025-11-06 | $5.54M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $22.34M 10-Q · filed 2026-08-06 | $34.44M 10-Q · filed 2026-08-06 | $3.25M derived: sum of 3 quarters · filed 2026-08-06 | $2.98M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $12.11M 10-Q · filed 2026-05-07 | -$19.08M derived: sum of 2 quarters · filed 2026-05-07 | -$19.35M derived: sum of 3 quarters · filed 2026-05-07 | -$13.48M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$31.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$31.46M derived: sum of 2 quarters · filed 2026-02-27 | -$25.58M derived: sum of 3 quarters · filed 2026-02-27 | -$117.36M 10-K · filed 2026-02-27 | |
| 2024-09-30 | -$267.00K 10-Q · filed 2025-11-06 | $5.61M derived: sum of 2 quarters · filed 2025-11-06 | -$86.17M 10-Q · filed 2025-11-06 | -$187.58M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $5.88M 10-Q · filed 2025-08-07 | -$85.90M 10-Q · filed 2025-08-07 | -$187.31M derived: sum of 3 quarters · filed 2026-02-27 | -$171.77M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | -$91.78M 10-Q · filed 2025-05-07 | -$193.18M derived: sum of 2 quarters · filed 2026-02-27 | -$177.64M derived: sum of 3 quarters · filed 2026-02-27 | -$155.41M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | -$101.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$85.87M derived: sum of 2 quarters · filed 2026-02-27 | -$63.63M derived: sum of 3 quarters · filed 2026-02-27 | -$79.27M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $15.54M 10-Q · filed 2024-11-12 | $37.77M derived: sum of 2 quarters · filed 2024-11-12 | $22.14M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $22.23M 10-Q · filed 2024-08-09 | $6.60M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$15.63M 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | -$270.58M 10-K · filed 2025-02-28 | ||||
| 2020-03-31 | $120.43M 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | -$52.66M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |